This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
« Back
Page 1 of 582

Advaxis: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy

By Adam Feuerstein

The hiring of a key Merck scientist and potential for combination cancer immunotherapy explain the recent rebound in Advaxis' stock price.

09:53AM 01/27/15

Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

06:00AM 01/23/15

8 Biotech Stock Controversies Emerging From 'JPM15' Conference

By Adam Feuerstein

The J.P. Morgan Healthcare Conference is in the rear-view mirror, but issues, controversies and questions raised during the annual gathering of the biotech sector tribe will linger through the year.

10:18AM 01/20/15

Express Scripts CEO: Amgen, Regeneron Among Targets for Drug Discounting

By Adam Feuerstein

Express Scripts CEO George Paz doesn't mince words about the need to cap specialty drug pricing during his talk Tuesday at the J.P. Morgan Healthcare Conference.

12:46PM 01/13/15

Aegerion Target of SEC Probe Related to Drug Sales Practices

By Adam Feuerstein

Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.

09:12AM 01/13/15

BioMarin Shows Up Rival Sarepta During 'JPM15' Investor Presentation

By Adam Feuerstein

Included in Bienaime's investor presentation is two slides making a direct data comparison between BioMarin's (soon to be) Duchenne muscular dystrophy drug drisapersen and Sarepta's competing DMD drug eteplirsen.

02:38PM 01/12/15

MannKind Gets Little Love From Sanofi at 'JPM15' Presentation

By Adam Feuerstein

The timing of the Afrezza commercial launch is still a mystery following Sanofi's presentation.

01:35PM 01/12/15

Celgene Has 2020 Vision for Long-Term Growth but Plays Safe for 2017

By Adam Feuerstein

Celgene CEO Bob Hugin just wrapped his presentation at the J.P. Morgan Healthcare Conference by reiterating 2017 financial guidance and offering new, longer-term guidance for 2020.

11:40AM 01/12/15

Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year

By Adam Feuerstein

The company presents at the J.P. Morgan Healthcare Conference on Thursday.

09:47AM 01/12/15

Bristol-Myers Checkpoint Inhibitor Prolongs Lung Cancer Patient Survival

By Adam Feuerstein

Lung cancer is a larger commercial market opportunity for Bristol's Opdivo and Merck's Keytruda.

07:07AM 01/12/15

« Back
Page 1 of 582

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs